Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 10/20 | 0.86 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14701325 | 0.93 | PRCP (0.86) | PRCPTACR3DRD4MAPTSMN1; SMN2 | |
| SCHEMBL12185627 | 0.92 | PRCP (1.00) | PRCPMAPTSMN1; SMN2 | |
| SCHEMBL12185983 | 0.91 | PRCP (0.85) | PRCPCHRM4DRD4NTSR1CCKAR | |
| SCHEMBL14701327 | 0.85 | PRCP (0.84) | PRCPDRD4CCKAR | |
| SCHEMBL12185581 | 0.85 | PRCP (1.00) | PRCPDRD4 | |
| SCHEMBL12185582 | 0.83 | PRCP (1.00) | PRCPMAPTSMN1; SMN2 | |
| SCHEMBL14701324 | 0.80 | PRCP (0.66) | PRCPDRD4MAPTSMN1; SMN2 | |
| SCHEMBL12186022 | 0.79 | PRCP (0.68) | PRCPDRD4 | |
| SCHEMBL14686708 | 0.78 | PRCP (0.65) | PRCPMAPTSMN1; SMN2 | |
| SCHEMBL14701354 | 0.77 | PRCP (0.84) | PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2568812-B1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2568812-B1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011143057-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885TACR3 4717/4885CHRM4 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.